Abstracts tagged "Rheumatoid Factor"

Abstract Number: 0157 • ACR Convergence 2020
Early Arthritis Global Assesment: What Differences Exist Between Patients and Physicians?
Cristina Valero¹, Noelia Garcia¹, Juan Pablo Baldivieso², Ana Ortiz³, Sebastian Rodriguez² and Isidoro González-Álvaro³, ¹Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ²Hospital de La Princesa, Madrid, Madrid, Spain, ³Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: In recent years there is increasing evidence of the relevance of including the assessment of the different aspects of rheumatoid arthritis (RA) from the…
Abstract Number: 0182 • ACR Convergence 2020
Chronic Kidney Disease Is Underestimated in Patients with Rheumatoid Arthritis – Real World Data Gathered from a Network of Rheumatologists
Stefan Kleinert¹, Peter Bartz-Bazzanella², Cay von der Decken³, Kirsten Karberg⁴, Florian Schuch⁵, Georg Gauler⁶, Patrick Wurth⁷, Susanna Spaethling-Mestekemper⁸, Christoph Kuhn⁹, Matthias Englbrecht¹⁰, Wolfgang Vorbrueggen¹¹ and Martin Welcker¹², ¹Rheumatology-Nephrology Practice, Erlangen, Germany, ²Department of Rheumatology, Internal Medicine, Rhein-Maas-Hospital, Wuerselen, Germany, ³Medical Centre Stolberg, Stolberg, Germany, ⁴Practice for Rheumatology and Internal Medicine, Berlin, Germany, ⁵Rheumatology-Nephrology Practice, Erlangen, ⁶Rheumatology Practice, Osnabrueck, ⁷Rheumatology Practice, Osnabrueck, Germany, ⁸Rheumatology Group Practice, Muenchen, Germany, ⁹Rheumatology Practice, Karlsruhe, ¹⁰Freelance Healthcare Data Scientist, Eckental, Germany, ¹¹Foundation for fostering rheumatology, Wuerselen, Germany, ¹²MVZ für Rheumatologie Dr. M. Welcker, Planegg, Germany
Background/Purpose: Patient registries have become a common approach to learn from patient-related data by prospectively including large numbers of individuals into a sample followed over…
Abstract Number: 145 • 2020 Pediatric Rheumatology Symposium
Anti-Citrullinated Protein Antibodies (ACPA) and Bony Erosions in Polyarticular JIA
Saumya Joshi¹, Yujuan Zhang ¹ and Trevor Davis ², ¹Tufts Medical Center, Boston, Massachusetts, ²Norwell, Massachusetts
Background/Purpose: Despite being a well-established biomarker for classification of aggressive bony disease in adults with RA, ACPA have not yet been described in the ILAR…
Abstract Number: 51 • 2019 ACR/ARP Annual Meeting
Cigarette Smoking Has Different Impacts on ACPA and RF Production Depending on Shared Epitope Allele Status in Japanese RA Patients; A Study with the Two Independent Japanese Cohorts (IORRA and KURAMA)
Yuki Ishikawa¹, Motomu Hashimoto ², Katsunori Ikari ³, Koichiro Ohmura ⁴, Masao Tanaka ⁴, Hiromu Ito ⁴, Atsuo Taniguchi ³, Hisashi Yamanaka ³, Tsuneyo Mimori ⁴ and Chikashi Terao ⁵, ¹Joslin Diabes Center, Boston, MA, ²Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Tokyo Women’s Medical University, Tokyo, Japan, ⁴Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵RIKEN, Tokyo, Japan
Background/Purpose: In rheumatoid arthritis (RA), cigarette smoking affects both rheumatoid factor (RF) and anti-citrullinated cyclic peptide/protein antibody (ACPA) production, but its association in relation to…
Abstract Number: 464 • 2019 ACR/ARP Annual Meeting
Continuous Decrease in Serum RF Titer During Anti-TNF Therapy Was Associated with Suppression in Progression of RA Joint Damage
Takayoshi Owada¹, Kazuhiro Kurasawa ¹, Yuta Takamura ¹, Toshiyuki Miyao ¹, Ayae Tanaka ¹, Ryutaro Yamazaki ¹, Satoko Arai ¹, Reika Maezawa ¹ and Masafumi Arima ¹, ¹Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi, Japan
Background/Purpose: A number of studies have investigated the association between serum RF and joint damage in early and established RA patients, and positive and high-titer…
Abstract Number: 1470 • 2018 ACR/ARHP Annual Meeting
Russell Bodies and Serological Status in Rheumatoid Arthritis
Michael A. McNamara¹, Susan M. Goodman², Laura T. Donlin³, Dana Orange⁴, Serene Z. Mirza¹, Jackie Szymonifka², Mark P. Figgie⁵, Vivian P. Bykerk² and Edward F. DiCarlo⁶, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ⁴Rockefeller University, New York, NY, ⁵Surgery, Hospital for Special Surgery, New York, NY, ⁶Laboratory Medicine, Hospital for Special Surgery, New York, NY
Russell Bodies and Serological Status in Rheumatoid Arthritis Background/Purpose: Russell bodies (RBs) are globular aggregates of immunoglobulin produced by plasma cells and identified both within…
Abstract Number: 1473 • 2018 ACR/ARHP Annual Meeting
Performance of the Meso Scale Multiplex Platform in the Assessment of Serum Cytokines / Chemokines in Rheumatoid Arthritis
Peter M. Maloley¹, Bryant R. England², Harlan Sayles¹, Geoffrey M. Thiele¹, Michael J. Duryee³, Jeffrey Payne⁴ and Ted R. Mikuls⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, ⁵Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cytokines and chemokines (CK) are central to RA pathogenesis, a fact underscored by the emergence of multiplex immunoassays for quantifying CK values in both…
Abstract Number: 1483 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical Features of Seronegative and Seropositive Early Rheumatoid Arthritis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients
Giampaolo Giacovelli, Beatrice Barbetta, Cristina Vitalini, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: Rheumatoid arthritis patients positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibody (ACPA) are considered to manifest an aggressive disease course compared with…
Abstract Number: 1503 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Factor Positivity Is Related with Higher Discontinuation Rate of Tumor Necrosis Factor Inhibitor Therapy Due to Adverse Event and Insufficient Response in Rheumatoid Arthritis: A Multiple Imputation Method for COX Proportional Hazard Model
Yoshikazu Ogawa¹, Nobunori Takahashi², Toshihisa Kojima² and Naoki Ishiguro², ¹Nakatsugawa Municipal General Hospital, Nakatsugawa, Japan, ²Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Discontinuation of tumor necrosis factor inhibitor (TNFi) therapy in rheumatoid arthritis (RA) is attributable to various reasons. Above all, adverse event (AE) and insufficient…
Abstract Number: 1504 • 2018 ACR/ARHP Annual Meeting
Utility of Serial ACPA Measurements in Rheumatoid Arthritis: Results of a Prospective Cohort Study
Alistair Reid^1,2,3, Michael D Wiese⁴, Robert Metcalf⁵, Mihir D Wechalekar^6,7, Anita Lee^8,9, Catherine Hill^2,10,11, Cindy Hall⁸, Leah McWilliams⁵, Les Cleland⁸ and Susanna Proudman¹², ¹Rheumatology, Royal Adelaide Hospital, NORTH ADELAIDE, Australia, ²Medicine, The University of Adelaide, Adelaide, Australia, ³Medicine, University of Wollongong, Wollongong, Australia, ⁴School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, ⁵Rheumatology Unit, Royal Adelaide Hospital, South Australia, Adelaide, Australia, ⁶Royal Adelaide Hospital, Adelaide, Australia, ⁷Rheumatology, Flinders University, Adelaide, Australia, ⁸Rheumatology, Royal Adelaide Hospital, Adelaide, Australia, ⁹Rheumatology, University of Adelaide, Adelaide, Australia, ¹⁰The Queen Elizabeth Hospital, Adelaide, Australia, ¹¹Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ¹²Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia
Background/Purpose: Anti-citrullinated peptide antibody (ACPA) and rheumatoid factor (RF) define “seropositive” rheumatoid arthritis (RA). Both predict disease course, development of extra-articular features and treatment outcomes.…
Abstract Number: 1858 • 2018 ACR/ARHP Annual Meeting
An Assay Panel Combining Anti-Protein Arginine Deiminase 4 with Rheumatoid Factor Isotypes Distinguishes Anti-Citrullinated Peptide Antibody Negative Rheumatoid Arthritis
Thierry Dervieux¹, Laura Martinez Prat², John Conklin¹, Claudia Ibarra¹, Michael Mahler², Michael E Weinblatt³ and Joel Kremer⁴, ¹Exagen Diagnostics, Inc., Vista, CA, ²Research and Development, Inova Diagnostics, San Diego, CA, ³Brigham and Women's Hospital, Boston, MA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Anti-citrullinated peptide antibodies (ACPAs) are highly specific for rheumatoid arthritis (RA) but lack sensitivity. We evaluated autoantibodies to protein-arginine deiminase 4 (anti-PAD4) in distinguishing…
Abstract Number: 1909 • 2018 ACR/ARHP Annual Meeting
Impact and Timing of Smoking Cessation on Reducing Risk for Seropositive Rheumatoid Arthritis Among Women
Xinyi Liu¹, Cianna Leatherwood¹, Sara K. Tedeschi¹, Medha Barbhaiya², Cameron Speyer¹, Bing Lu³, Karen Costenbader¹, Elizabeth Karlson¹ and Jeffrey A. Sparks¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Compared to never smoking, past and current smoking are both associated with increased risk of seropositive rheumatoid arthritis (RA). Thus, smoking cessation may delay…
Abstract Number: 2046 • 2018 ACR/ARHP Annual Meeting
Serum Immunoglobulin G Targets Citrulline-Containing Immunoglobulin G Peptides in Rheumatoid Arthritis Patients Who Test Positive for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibodies
Mandar Bawadekar¹, Zihao Zheng², Alan J. Bridges^3,4, Michael A. Newton⁵ and Miriam A. Shelef^1,4, ¹Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, Madison, WI, ²Departments of Statistics, University of Wisconsin - Madison, Madison, WI, ³Medicine, University of Wisconsin - Madison, Madison, WI, ⁴William S. Middleton Memorial Veterans Hospital, Madison, WI, ⁵Departments of Statistics and of Biostatistics and Medical Informatics, University of Wisconsin - Madison, Madison, WI
Background/Purpose: Rheumatoid arthritis patients produce a variety of anti-citrullinated protein antibodies (ACPAs) as well as antibodies that bind homocitrullinated and malondialdehyde-acetaldehyde adducted proteins leading to…
Abstract Number: 2051 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Factor Peptide Expression By Quantitative Proteomics Delineates Responsive and Resistant Clones after Treatment of Early Rheumatoid Arthritis
Jing Jing Wang¹, William Murray-Brown², Alexander Colella¹, Malcolm D. Smith³, Tim Chataway⁴, Jenny Walker², William H. Robinson⁵, Mihir D Wechalekar² and Tom Gordon^1,6, ¹Immunology, Flinders University, Adelaide, Australia, ²Rheumatology, Flinders University, Adelaide, Australia, ³Rheumotology, Flinders University, Adelaide, Australia, ⁴Proteomic Facility, Flinders University, Adelaide, Australia, ⁵Stanford University, Palo Alto, CA, ⁶Immunology, SA Pathology, Adelaide, Australia
Background/Purpose: Rheumatoid factors (RFs) are associated with disease activity and joint damage in rheumatoid arthritis (RA) and thought to play a pathogenic role in disease.…
Abstract Number: 2054 • 2018 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis, Changes in Autoantibody Levels Do Not Associate with Treatment Response, but Are a Reflection of Treatment Intensity
Emma de Moel¹, Veerle Derksen¹, LA Trouw¹, Holger Bang², Gerard Collée³, L.R. Lard⁴, Tom W.J. Huizinga⁵, Cornelia F. Allaart⁶, René E.M. Toes⁵ and Diane van der Woude⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Rheumatology, Haaglanden Medical Center Antoniushove, Leidschendam, Netherlands, ⁴Rheumatology, LUMC, Leiden, Netherlands, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Department of Rheumatology, LUMC, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is characterized by the presence of autoantibodies like rheumatoid factor (RF), anti-cyclic citrullinated peptide-2 (anti-CCP2), & anti-carbamylated protein (anti-CarP) antibodies. It…

« Previous Page
1
…
5
6
7
8
9
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].